Invitae Reports $460.4 Million in Annual Revenue Driven by 1.17 Million in Billable Volume in 2021

Rhea-AI Summary

Invitae (NYSE: NVTA) reported its financial results for Q4 and the full year 2021, generating revenues of $460.4 million, with $126.1 million in Q4. The company saw significant growth in patient volume, reaching 1.17 million billable tests in 2021. However, it reported a net loss of $379.0 million for the year. Invitae anticipates a revenue growth of 40% in 2022, targeting around $640 million. Cash reserves decreased to $1.06 billion as of December 31, 2021, with an expected cash burn of $600-$650 million for 2022.

Positive

• Generated revenues of $460.4 million in 2021, a significant increase.
• Achieved a billable volume of 1.17 million tests in 2021.
• Total active healthcare provider accounts grew to 18,458, up over 50% since 2020.
• Active pharma partnerships increased to 178, a growth of around 170% since 2020.
• Issued guidance for 2022 with expected revenue growth of 40%, targeting $640 million.

Negative

• Reported a net loss of $379.0 million for the full year 2021.
• Q4 2021 net loss was $205.1 million, representing a $0.90 net loss per share.
• Cash reserves decreased from $1.25 billion to $1.06 billion within Q4.
• Cash burn for Q4 2021 was $195.6 million.

SAN FRANCISCO, Feb. 24, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and year ended December 31, 2021.

"2021 was another year of industry leading growth and the addition of almost 1 million patients onto the Invitae platform, providing further evidence that the Invitae vision and one-of-a-kind testing, digital health and data network are ushering in the era of genomic health management," said Sean George, Ph.D., co-founder and CEO of Invitae. "Looking into 2022, we intend to maintain our focus on driving that shift to a healthcare ecosystem underscored by genomic information and management, while demonstrating operational excellence and charting a clear path towards operating cash flows."

Full Year and Fourth Quarter 2021 Financial Results

• Generated revenue of $460.4 million in 2021, including $126.1 million in the fourth quarter.
• Reported billable volume of 1.17 million in 2021, including 327,000 in the fourth quarter.
• Total active healthcare provider accounts in 2021 totaled 18,458, more than 50 percent growth since the beginning of 2020.
• Active pharma and commercial partnerships grew to 178, an increase of approximately 170 percent since the beginning of 2020 driving continued revenue growth from Invitae's data and data services platform to pharma, health system and software and services partners.
• Total patient population is more than 2.5 million with over 62 percent available for data sharing.
• Achieved gross profit of $111.8 million in 2021, including $30.0 million in the fourth quarter. Non-GAAP gross profit was $168.4 million in 2021, and $46.0 million in the fourth quarter.

Total operating expense, which excludes cost of revenue, for the full year 2021 was $503.4 million. Operating expense for the fourth quarter of 2021 was $244.6 million. Non-GAAP operating expense was $771.1 million for the full year 2021, and $215.7 million in the fourth quarter.

Net loss for the full year 2021 was $379.0 million, or a $1.80 net loss per share. For the fourth quarter of 2021, Invitae reported a net loss of $205.1 million, or a $0.90 net loss per share. Non-GAAP net loss was $654.3 million, or a $3.10 non-GAAP net loss per share in 2021. For the fourth quarter of 2021, Invitae reported a non-GAAP net loss of $184.7 million, or a $0.81 non-GAAP net loss per share.

At December 31, 2021, cash, cash equivalents, restricted cash and marketable securities totaled $1.06 billion as compared with $1.25 billion as of September 30, 2021. Net increase in cash, cash equivalents, restricted cash, and marketable securities was $695 million in 2021, and a net decrease of $196.7 million for the fourth quarter. Cash burn was $195.6 million in the fourth quarter of 2021. Cash burn for the quarter would have been $186.1 million excluding the cash paid for acquisitions.

Guidance 
The company has issued 2022 annual revenue guidance of year-over-year revenue growth of 40 percent, or approximately $640 million. New guidance categories for 2022 include gross margin and cash burn measures. Gross margin for 2022 is expected to be between 42-45 percent with cash burn, including cash used for acquisition-related activities, expected to be in the range of $600-$650 million in 2022, a more than $200 million year-over-year reduction.

Webcast and Conference Call Details 
Management will host a conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss financial results and recent developments. To access the conference call, please register at the link below:

https://conferencingportals.com/event/DqFqYhVe 

Upon registering, each participant will be provided with call details and a conference ID.

The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website.

About Invitae 
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.

Safe Harbor Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's beliefs regarding its vision and that its results evidence its belief that it is ushering in the era of genomic health management; the company's future financial and operating results, including guidance for 2022, and the drivers of future financial results; the company's beliefs regarding the momentum in its business and the drivers of that momentum; the company's expectations regarding future growth; the company's focus for 2022, and its expectations regarding charting a path toward future operating cash flows; expectations regarding future product introductions and expansions; and the impact and benefits of the company's acquisitions, partnerships and product offerings. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the impact of COVID-19 on the company, and the effectiveness of the efforts it has taken or may take in the future in response thereto; the impact of inflation; the company's ability to continue to grow its business, including internationally; the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the ability of the company to obtain regulatory approval for its tests; the applicability of clinical results to actual outcomes; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Non-GAAP financial measures 
To supplement Invitae's consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP), the company is providing several non-GAAP measures, including non-GAAP gross profit, non-GAAP cost of revenue, non-GAAP operating expense, including non-GAAP research and development, non-GAAP selling and marketing, non-GAAP general and administrative and non-GAAP other income (expense), net, as well as non-GAAP net loss and non-GAAP net loss per share and non-GAAP cash burn. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-GAAP financial measures are useful to investors in evaluating the company's ongoing operating results and trends.

Management is excluding from some or all of its non-GAAP operating results (1) amortization of acquired intangible assets, (2) acquisition-related stock-based compensation, (3) post-combination expense related to the acceleration of equity grants or bonus payments in connection with the company's acquisitions, (4) adjustments to the fair value of acquisition-related assets and/or liabilities, including contingent consideration and (5) acquisition-related income tax benefits. These non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in the company's public disclosures.

Cash burn excludes (1) changes in marketable securities, (2) cash received from equity or debt financings and (3) cash received from exercises of warrants. Management believes cash burn is a liquidity measure that provides useful information to management and investors about the amount of cash consumed by the operations of the business. A limitation of using this non-GAAP measure is that cash burn does not represent the total change in cash, cash equivalents, and restricted cash for the period because it excludes cash provided by or used for other operating, investing or financing activities. Management accounts for this limitation by providing information about the company's operating, investing and financing activities in the statements of cash flows in the consolidated financial statements in the company's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and by presenting net cash provided by (used in) operating, investing and financing activities as well as the net increase or decrease in cash, cash equivalents and restricted cash in its reconciliation of cash burn.

In addition, other companies, including companies in the same industry, may not use the same non-GAAP measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. Because of these limitations, the company's non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the non-GAAP reconciliations provided in the tables below.

 

INVITAE CORPORATION
Consolidated Balance Sheets
(in thousands)
(unaudited)
	December 31,
	2021		2020
Assets
Current assets:
Cash and cash equivalents	$         923,250		$         124,794
Marketable securities	122,121		229,186
Accounts receivable	66,227		47,722
Inventory	33,516		32,030
Prepaid expenses and other current assets	33,691		20,200
Total current assets	1,178,805		453,932
Property and equipment, net	114,714		66,102
Operating lease assets	121,169		45,109
Restricted cash	10,275		6,686
Intangible assets, net	1,187,994		981,845
Goodwill	2,283,059		1,863,623
Other assets	23,551		13,188
Total assets	$      4,919,567		$      3,430,485
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$           21,127		$           25,203
Accrued liabilities	106,453		86,058
Operating lease obligation	12,359		8,789
Finance lease obligation	4,156		1,695
Total current liabilities	144,095		121,745
Operating lease obligation, net of current portion	124,369		48,357
Finance lease obligation, net of current portion	5,683		3,123
Debt	113,391		104,449
Convertible senior notes, net	1,464,138		283,724
Deferred tax liability	51,696		51,538
Other long-term liabilities	37,797		841,256
Total liabilities	1,941,169		1,454,192
Stockholders' equity:
Common stock	23		19
Accumulated other comprehensive (loss) income	(7)		1
Additional paid-in capital	4,701,230		3,337,120
Accumulated deficit	(1,722,848)		(1,360,847)
Total stockholders' equity	2,978,398		1,976,293
Total liabilities and stockholders' equity	$      4,919,567		$      3,430,485

 

 

INVITAE CORPORATION
Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
		Three Months Ended December 31,				Year Ended December 31,
		2021		2020		2021		2020
Revenue:
Test revenue		$        121,624		$          96,807		$        444,072		$        272,310
Other revenue		4,497		3,624		16,377		7,288
Total revenue		126,121		100,431		460,449		279,598
Cost of revenue		96,106		68,258		348,669		198,275
Research and development		131,764		72,172		416,087		240,605
Selling and marketing		62,205		48,877		225,910		168,317
General and administrative		50,430		192,290		248,070		270,029
Change in fair value of contingent consideration		190		50,317		(386,646)		54,544
Total costs and operating expenses		340,695		431,914		852,090		931,770
Loss from operations		(214,574)		(331,483)		(391,641)		(652,172)
Other income (expense), net		15,832		167		25,678		(32,332)
Interest expense		(14,031)		(12,522)		(49,900)		(29,766)
Net loss before taxes		(212,773)		(343,838)		(415,863)		(714,270)
Income tax benefit		(7,649)		(109,500)		(36,857)		(112,100)
Net loss		$       (205,124)		$       (234,338)		$       (379,006)		$       (602,170)
Net loss per share, basic and diluted		$             (0.90)		$             (1.30)		$             (1.80)		$             (4.47)
Shares used in computing net loss per share, basic and diluted		226,849		179,860		210,946		134,587

 

 

INVITAE CORPORATION
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
	Year Ended December 31,
	2021		2020		2019
Cash flows from operating activities:
Net loss	$       (379,006)		$      (602,170)		$      (241,965)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	80,472		39,050		16,206
Stock-based compensation	180,075		158,747		75,948
Amortization of debt discount and issuance costs	14,226		17,204		4,416
Remeasurements of liabilities associated with business combinations	(411,842)		92,348		—
Benefit from income taxes	(36,857)		(112,100)		(18,450)
Debt extinguishment costs	—		—		8,926
Post-combination expense for acceleration of unvested equity and deferred stock compensation	9,530		91,021		—
Amortization of premiums and discounts on investment securities	6,221		1,236		(296)
Other	4,983		189		1,391
Changes in operating assets and liabilities, net of businesses acquired:
Accounts receivable	(16,696)		(2,814)		(6,131)
Inventory	(1,486)		(7,832)		1,645
Prepaid expenses and other current assets	(14,563)		(2,010)		(6,624)
Other assets	(3,274)		895		2,026
Accounts payable	(9,258)		10,186		1,558
Accrued expenses and other long-term liabilities	17,660		17,548		16,297
Net cash used in operating activities	(559,815)		(298,502)		(145,053)
Cash flows from investing activities:
Purchases of marketable securities	(325,957)		(280,258)		(260,917)
Proceeds from sales of marketable securities	—		12,832		—
Proceeds from maturities of marketable securities	425,293		277,487		34,500
Acquisition of businesses, net of cash acquired	(247,396)		(383,753)		(33,846)
Purchases of property and equipment	(54,720)		(22,865)		(20,047)
Other	(1,300)		(4,026)		—
Net cash used in investing activities	(204,080)		(400,583)		(280,310)
Cash flows from financing activities:
Proceeds from public offerings of common stock, net	434,263		263,688		204,024
Proceeds from issuance of common stock	23,767		284,203		9,470
Proceeds from issuance of convertible senior notes, net	1,116,427		—		339,900
Proceeds from issuance of debt, net	—		129,214		—
Payments of debt extinguishment costs	—		—		(10,638)
Loan payments	—		—		(75,000)
Finance lease principal payments	(3,759)		(2,655)		(2,075)
Other	(4,758)		(1,457)		(910)
Net cash provided by financing activities	1,565,940		672,993		464,771
Net increase (decrease) in cash, cash equivalents and restricted cash	802,045		(26,092)		39,408
Cash, cash equivalents and restricted cash at beginning of period	131,480		157,572		118,164
Cash, cash equivalents and restricted cash at end of period	$        933,525		$        131,480		$        157,572

 

 

INVITAE CORPORATION
Reconciliation of GAAP to Non-GAAP Cost of Revenue
(in thousands)
(unaudited)
		Three Months Ended December 31,				Year Ended December 31,
		2021		2020		2021		2020
Cost of revenue		$         96,106		$         68,258		$      348,669		$      198,275
Amortization of acquired intangible assets		(15,392)		(9,805)		(49,970)		(21,943)
Acquisition-related stock-based compensation		(141)		(1,954)		(2,461)		(1,954)
Acquisition-related post-combination expense		(479)		—		(1,058)		—
Fair value adjustments to acquisition-related assets		—		(1,574)		(3,148)		(1,574)
Non-GAAP cost of revenue		$         80,094		$         54,925		$      292,032		$      172,804

 

Reconciliation of GAAP to Non-GAAP Gross Profit
(in thousands)
(unaudited)
		Three Months Ended December 31,				Year Ended December 31,
		2021		2020		2021		2020
Revenue		$       126,121		$       100,431		$       460,449		$       279,598
Cost of revenue		96,106		68,258		348,669		198,275
Gross profit		30,015		32,173		111,780		81,323
Amortization of acquired intangible assets - cost of revenue		15,392		9,805		49,970		21,943
Acquisition-related stock-based compensation		141		1,954		2,461		1,954
Acquisition-related post-combination expense		479		—		1,058		—
Fair value adjustments to acquisition-related assets		—		1,574		3,148		1,574
Non-GAAP gross profit		$         46,027		$         45,506		$       168,417		$       106,794

 

Reconciliation of GAAP to Non-GAAP Research and Development Expense
(in thousands)
(unaudited)
		Three Months Ended December 31,				Year Ended December 31,
		2021		2020		2021		2020
Research and development		$       131,764		$         72,172		$      416,087		$      240,605
Amortization of acquired intangible assets		(529)		(470)		(2,117)		(820)
Acquisition-related stock-based compensation		(23,703)		(16,204)		(44,406)		(68,215)
Acquisition-related post-combination expense		(2,607)		(60)		(6,056)		(120)
Non-GAAP research and development		$       104,925		$         55,438		$      363,508		$      171,450

 

 

INVITAE CORPORATION
Reconciliation of GAAP to Non-GAAP Selling and Marketing Expense
(in thousands)
(unaudited)
		Three Months Ended December 31,				Year Ended December 31,
		2021		2020		2021		2020
Selling and marketing		$         62,205		$         48,877		$      225,910		$      168,317
Amortization of acquired intangible assets		(1,686)		(1,536)		(6,748)		(3,868)
Acquisition-related stock-based compensation		—		(3,155)		(2,696)		(3,155)
Acquisition-related post-combination expense		—		(40)		(38)		(80)
Non-GAAP selling and marketing		$         60,519		$         44,146		$      216,428		$      161,214

 

Reconciliation of GAAP to Non-GAAP General and Administrative Expense
(in thousands)
(unaudited)
		Three Months Ended December 31,				Year Ended December 31,
		2021		2020		2021		2020
General and administrative		$         50,430		$       192,290		$      248,070		$      270,029
Amortization of acquired intangible assets		—		—		—		(10)
Acquisition-related stock-based compensation		(32)		(20,147)		(21,293)		(20,147)
Acquisition-related post-combination expense		(165)		(125,842)		(35,628)		(126,342)
Non-GAAP general and administrative		$         50,233		$         46,301		$      191,149		$      123,530

 

Reconciliation of Operating Expense to Non-GAAP Operating Expense
(in thousands)
(unaudited)
		Three Months Ended December 31,				Year Ended December 31,
		2021		2020		2021		2020
Research and development		$       131,764		$         72,172		$      416,087		$      240,605
Selling and marketing		62,205		48,877		225,910		168,317
General and administrative		50,430		192,290		248,070		270,029
Change in fair value of contingent consideration		190		50,317		(386,646)		54,544
Operating expense		244,589		363,656		503,421		733,495
Amortization of acquired intangible assets		(2,215)		(2,006)		(8,865)		(4,698)
Acquisition-related stock-based compensation		(23,735)		(39,506)		(68,395)		(91,517)
Acquisition-related post-combination expense		(2,772)		(125,942)		(41,722)		(126,542)
Fair value adjustments to acquisition-related liabilities		(190)		(50,317)		386,646		(54,645)
Non-GAAP operating expense		$       215,677		$       145,885		$      771,085		$      456,093

 

 

INVITAE CORPORATION
Reconciliation of Other Income (Expense), Net to Non-GAAP Other Income (Expense), Net
(in thousands)
(unaudited)
		Three Months Ended December 31,				Year Ended December 31,
		2021		2020		2021		2020
Other income (expense), net		$         15,832		$              167		$        25,678		$       (32,332)
Fair value adjustments to acquisition-related liabilities		(16,017)		(410)		(25,196)		37,527
Non-GAAP other (expense) income, net		$            (185)		$            (243)		$            482		$          5,195

 

Reconciliation of Net Loss to Non-GAAP Net Loss And Non-GAAP Net Loss Per Share
(in thousands, except per share data)
(unaudited)
		Three Months Ended December 31,				Year Ended December 31,
		2021		2020		2021		2020
Net loss		$      (205,124)		$      (234,338)		$     (379,006)		$     (602,170)
Amortization of acquired intangible assets		17,607		11,811		58,835		26,641
Acquisition-related stock-based compensation		23,876		41,460		70,856		93,471
Acquisition-related post-combination expense		3,251		125,942		42,780		126,542
Fair value adjustments to acquisition-related assets and liabilities		(15,827)		51,481		(408,694)		93,746
Acquisition-related income tax benefit		(8,480)		(109,500)		(39,087)		(112,100)
Non-GAAP net loss		$      (184,697)		$      (113,144)		$     (654,316)		$     (373,870)
Net loss per share, basic and diluted		$            (0.90)		$            (1.30)		$          (1.80)		$          (4.47)
Non-GAAP net loss per share, basic and diluted		$            (0.81)		$            (0.63)		$          (3.10)		$          (2.78)
Shares used in computing net loss per share, basic and diluted		226,849		179,860		210,946		134,587

 

 

INVITAE CORPORATION
Reconciliation of Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash to Cash Burn
(in thousands)
(unaudited)
	Three Months Ended								Year Ended
	March 31, 2021		June 30, 2021		September 30, 2021		December 31, 2021		December 31, 2021
Net cash used in operating activities	$    (89,520)		$    (129,325)		$    (165,052)		$    (175,918)		$          (559,815)
Net cash (used in) provided by investing activities	(273,558)		(80,701)		(20,324)		170,503		(204,080)
Net cash provided by (used in) financing activities	436,091		1,123,553		(735)		7,031		1,565,940
Net increase (decrease) in cash, cash equivalents and restricted cash	73,013		913,527		(186,111)		1,616		802,045
Adjustments:
Net changes in investments	249,694		(51,475)		(100,305)		(197,250)		(99,336)
Proceeds from public offering of common stock, net of issuance costs	(434,263)		—		—		—		(434,263)
Proceeds from issuance of convertible senior notes, net	—		(1,116,850)		423		—		(1,116,427)
Proceeds from exercises of warrants	(790)		(452)		—		—		(1,242)
Cash burn	$  (112,346)		$    (255,250)		$    (285,993)		$    (195,634)		$          (849,223)
• Cash burn for the three months ended December 31, 2021 includes $9.5 million cash paid for acquisitions, primarily related to the cash paid to acquire Stratify Genomics, Inc.
• Cash burn for the three months ended September 30, 2021 includes $134.6 million of cash paid for acquisitions, primarily related to the cash paid to acquire Medneon and Ciitizen, and $3.3 million in acquisition-related transaction costs.
• Cash burn for the three months ended June 30, 2021 includes $120.1 million of cash paid for acquisitions, primarily related to the cash paid to acquire Genosity.
• Cash burn for the three months ended March 31, 2021 includes $17.7 million of cash paid for acquisitions, primarily related to the cash paid to acquire One Codex.

Contact for Invitae: 
Jack Finks 
ir@invitae.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/invitae-reports-460-4-million-in-annual-revenue-driven-by-1-17-million-in-billable-volume-in-2021--301490122.html

SOURCE Invitae Corporation

FAQ

What were Invitae's total revenues for 2021?

Invitae generated total revenues of $460.4 million in 2021.

What is Invitae's revenue guidance for 2022?

Invitae anticipates year-over-year revenue growth of 40%, targeting approximately $640 million in 2022.

How much was Invitae's net loss for 2021?

Invitae reported a net loss of $379.0 million for the full year 2021.

What was the cash burn for Invitae in Q4 2021?

Invitae's cash burn in Q4 2021 was $195.6 million.

How many billable tests did Invitae report in 2021?

Invitae reported a billable volume of 1.17 million tests in 2021.